49. 全身性エリテマトーデス
［臨床試験数：827，薬物数：638（DrugBank：168），標的遺伝子数：108，標的パスウェイ数：191］
Searched query = "Systemic lupus erythematosus", "SLE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04397107 (ClinicalTrials.gov) | August 15, 2020 | 6/5/2020 | The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases | The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases (Systemic Lupus Erythematosus, Primary Sjögren Syndrome, Juvenile Idiopathic Arthritis) | Systemic Lupus Erythematosus | Drug: IL-2 | First Hospital of Jilin University | NULL | Recruiting | N/A | 17 Years | All | 46 | N/A | China |
| 2 | NCT04077684 (ClinicalTrials.gov) | September 10, 2019 | 1/9/2019 | Efficacy and Safety of Low-dose IL-2 in Patients With SLE: a Multicenter, Randomised, Placebo-controlled Trial | Efficacy and Safety of Low-dose Interleukin-2 in Patients With Systemic Lupus Erythematosus: a Multicenter, Randomised, Placebo-controlled Trial | Systemic Lupus Erythematosus | Drug: Interleukin-2 | Peking University People's Hospital | NULL | Recruiting | 18 Years | 75 Years | All | 500 | Phase 2 | China |
| 3 | NCT03312335 (ClinicalTrials.gov) | August 8, 2018 | 29/9/2017 | Low-dose Interleukin-2 for Treatment of Systemic Lupus Erythematosus | Open-label, Monocentric, Phase II, Investigator-initiated Clinical Trial on Unbiased Characterization of Immunological Parameters in Interleukin-2-treated Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic | Drug: Low-dose Aldesleukin (Proleukin®) | Onur Boyman, MD | NULL | Completed | 18 Years | N/A | All | 16 | Phase 2 | Switzerland |
| 4 | EUCTR2016-000488-17-FR (EUCTR) | 16/05/2018 | 19/03/2019 | A study to evaluate the effectiveness and safety of the study drug, when patients are given dosage of ILT-101 with active moderate to severe systemic lupus erythematosus(SLE) | A Phase II, multi-centre, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety and pharmacokinetics of ILT-101 in patients with active moderate to severe systemic lupus erythematosus (SLE) | Systematic Lupus Erythematosus MedDRA version: 20.0;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: ILT-101 Product Code: ILT-101 INN or Proposed INN: Aldesleukin Other descriptive name: INTERLEUKIN-2 | ILTOO PHARMA | NULL | Not Recruiting | Female: yes Male: yes | 100 | Phase 2 | Portugal;France;Mexico;Spain;Austria;Bulgaria;Italy | ||
| 5 | EUCTR2016-000488-17-BG (EUCTR) | 27/03/2017 | 13/02/2017 | A study to evaluate the effectiveness and safety of the study drug, when patients are given dosage of ILT-101 with active moderate to severe systemic lupus erythematosus(SLE) | A Phase II, multi-centre, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety and pharmacokinetics of ILT-101 in patients with active moderate to severe systemic lupus erythematosus (SLE) | Systematic Lupus Erythematosus MedDRA version: 20.0;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: ILT-101 Product Code: ILT-101 INN or Proposed INN: Aldesleukin Other descriptive name: INTERLEUKIN-2 | ILTOO PHARMA | NULL | Not Recruiting | Female: yes Male: yes | 100 | Phase 2 | Portugal;France;Mexico;Spain;Romania;Austria;Bulgaria;Germany;Italy | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT02932137 (ClinicalTrials.gov) | May 5, 2016 | 8/10/2016 | Anti-infection of Low-does IL-2 in SLE | Potential Effect of Anti-infection by Low-dose IL-2 in Treatment of SLE | Systemic Lupus Erythematosus | Drug: Interleukin-2 | Peking University People's Hospital | NULL | Completed | 18 Years | 60 Years | All | 30 | N/A | China |
| 7 | EUCTR2013-001599-40-DE (EUCTR) | 03/01/2014 | 14/11/2013 | Evaluation of the therapeutic potential of a low-dose therapy with the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus. | Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus as prototypic autoimmune disease (PRO-IMMUN). A COMBINED PHASE I/IIA, PROSPECTIVE, OPEN-LABEL AND UNCONTROLLED SINGLE-CENTER STUDY TO ANALYSE SAFETY, TOLERABILITY, EFFICACY AND IMMUNOLOGICAL RESPONSES OF LOW-DOSE SUBCUTANEOUS INTERLEUKIN-2 (ALDESLEUKIN, PROLEUKIN®) IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND INCREASED DISEASE ACTIVITY REFRACTORY TO STANDARD THERAPIES. - PRO-IMMUN | Patients with systemic lupus erythematosus (SLE) and increased disease activity refractory to standard therapies. MedDRA version: 18.0;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 18.0;Classification code 10067657;Term: Systemic lupus erythematosus disease activity index increased;System Organ Class: 10022891 - Investigations ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Charité - Universitätsmedizin Berlin | NULL | Not Recruiting | Female: yes Male: yes | 12 | Phase 1;Phase 2 | Germany | |||
| 8 | NCT02084238 (ClinicalTrials.gov) | August 2013 | 8/3/2014 | Low-dose IL-2( Interleukin-2) Treatment in SLE | Safety and Efficiency Study of Low-dose IL-2 Treatment in Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Drug: Interleukin-2 | Peking University People's Hospital | Monash University | Completed | 18 Years | 65 Years | All | 40 | N/A | China |